Real-world study of efficacy and safety of PD-1 antibody monotherapy and combination therapy in pediatric lymphoma patients
Abstract Purpose Pediatric lymphoma patients generally demonstrate a favorable long-term survival rate. The use of anti-programmed death-1 (PD-1) monoclonal antibodies has significantly improved the response rates in adult patients with refractory/relapsed lymphoma, particularly those with Hodgkin l...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-06-01
|
| Series: | Holistic Integrative Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s44178-025-00175-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850136882305826816 |
|---|---|
| author | Yingxia Lan Zizheng Xiao Yi Que Yi Wang Ye Hong Juan Wang Suying Lu Junting Huang Feifei Sun Zijun Zhen Juan Liu Jiaqian Xu Yanpeng Wu Lanying Guo M. James You Jia Zhu Yizhuo Zhang |
| author_facet | Yingxia Lan Zizheng Xiao Yi Que Yi Wang Ye Hong Juan Wang Suying Lu Junting Huang Feifei Sun Zijun Zhen Juan Liu Jiaqian Xu Yanpeng Wu Lanying Guo M. James You Jia Zhu Yizhuo Zhang |
| author_sort | Yingxia Lan |
| collection | DOAJ |
| description | Abstract Purpose Pediatric lymphoma patients generally demonstrate a favorable long-term survival rate. The use of anti-programmed death-1 (PD-1) monoclonal antibodies has significantly improved the response rates in adult patients with refractory/relapsed lymphoma, particularly those with Hodgkin lymphoma and NK/T cell lymphoma. This study aimed to evaluate the real-world efficacy and safety of PD-1 antibody monotherapy or combination therapy in pediatric lymphoma patients. Methods From March 1, 2017, to October 25, 2022, we retrospectively analyzed data from 41 pediatric lymphoma patients who received PD-1 antibody treatment, including those with Hodgkin lymphoma, extranodal NK/T cell lymphoma, primary mediastinal large B-cell lymphoma, and other subtypes. Kaplan–Meier analysis was used to estimate progression-free survival (PFS) and overall survival (OS). Descriptive statistics were used to report response rates and adverse effects. Results The median follow-up period was 22.4 months (range, 1.3–67.6 months), and the overall response rate for the entire cohort was 82.9% (51.2% complete response [CR], 31.7% partial response [PR]). Only two patients died due to disease progression. The two-year PFS rate was 63.0 ± 8.5%, and the median OS and PFS were not reached. PD-1 antibodies were generally well tolerated, particularly in patients receiving monotherapy. Conclusion Our findings suggest that PD-1 antibody treatment offers a high response rate and low toxicity in pediatric lymphoma patients. |
| format | Article |
| id | doaj-art-311fb689d95048bea29a62d5fff3f37e |
| institution | OA Journals |
| issn | 2731-4529 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Springer |
| record_format | Article |
| series | Holistic Integrative Oncology |
| spelling | doaj-art-311fb689d95048bea29a62d5fff3f37e2025-08-20T02:31:00ZengSpringerHolistic Integrative Oncology2731-45292025-06-014111010.1007/s44178-025-00175-3Real-world study of efficacy and safety of PD-1 antibody monotherapy and combination therapy in pediatric lymphoma patientsYingxia Lan0Zizheng Xiao1Yi Que2Yi Wang3Ye Hong4Juan Wang5Suying Lu6Junting Huang7Feifei Sun8Zijun Zhen9Juan Liu10Jiaqian Xu11Yanpeng Wu12Lanying Guo13M. James You14Jia Zhu15Yizhuo Zhang16State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterDepartment of Pediatric Oncology, the 5 th affiliated hospital of Guangzhou Medical UniversityDepartment of Pediatric Oncology, the 5 th affiliated hospital of Guangzhou Medical UniversityDepartment of Pediatric Oncology, the 5 th affiliated hospital of Guangzhou Medical UniversityDepartment of Pediatric Oncology, the 5 th affiliated hospital of Guangzhou Medical UniversityDepartment of Hematopathology, The University of Texas MD Anderson Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterAbstract Purpose Pediatric lymphoma patients generally demonstrate a favorable long-term survival rate. The use of anti-programmed death-1 (PD-1) monoclonal antibodies has significantly improved the response rates in adult patients with refractory/relapsed lymphoma, particularly those with Hodgkin lymphoma and NK/T cell lymphoma. This study aimed to evaluate the real-world efficacy and safety of PD-1 antibody monotherapy or combination therapy in pediatric lymphoma patients. Methods From March 1, 2017, to October 25, 2022, we retrospectively analyzed data from 41 pediatric lymphoma patients who received PD-1 antibody treatment, including those with Hodgkin lymphoma, extranodal NK/T cell lymphoma, primary mediastinal large B-cell lymphoma, and other subtypes. Kaplan–Meier analysis was used to estimate progression-free survival (PFS) and overall survival (OS). Descriptive statistics were used to report response rates and adverse effects. Results The median follow-up period was 22.4 months (range, 1.3–67.6 months), and the overall response rate for the entire cohort was 82.9% (51.2% complete response [CR], 31.7% partial response [PR]). Only two patients died due to disease progression. The two-year PFS rate was 63.0 ± 8.5%, and the median OS and PFS were not reached. PD-1 antibodies were generally well tolerated, particularly in patients receiving monotherapy. Conclusion Our findings suggest that PD-1 antibody treatment offers a high response rate and low toxicity in pediatric lymphoma patients.https://doi.org/10.1007/s44178-025-00175-3PediatricLymphomaPD-1 antibodiesToxicityReal-world |
| spellingShingle | Yingxia Lan Zizheng Xiao Yi Que Yi Wang Ye Hong Juan Wang Suying Lu Junting Huang Feifei Sun Zijun Zhen Juan Liu Jiaqian Xu Yanpeng Wu Lanying Guo M. James You Jia Zhu Yizhuo Zhang Real-world study of efficacy and safety of PD-1 antibody monotherapy and combination therapy in pediatric lymphoma patients Holistic Integrative Oncology Pediatric Lymphoma PD-1 antibodies Toxicity Real-world |
| title | Real-world study of efficacy and safety of PD-1 antibody monotherapy and combination therapy in pediatric lymphoma patients |
| title_full | Real-world study of efficacy and safety of PD-1 antibody monotherapy and combination therapy in pediatric lymphoma patients |
| title_fullStr | Real-world study of efficacy and safety of PD-1 antibody monotherapy and combination therapy in pediatric lymphoma patients |
| title_full_unstemmed | Real-world study of efficacy and safety of PD-1 antibody monotherapy and combination therapy in pediatric lymphoma patients |
| title_short | Real-world study of efficacy and safety of PD-1 antibody monotherapy and combination therapy in pediatric lymphoma patients |
| title_sort | real world study of efficacy and safety of pd 1 antibody monotherapy and combination therapy in pediatric lymphoma patients |
| topic | Pediatric Lymphoma PD-1 antibodies Toxicity Real-world |
| url | https://doi.org/10.1007/s44178-025-00175-3 |
| work_keys_str_mv | AT yingxialan realworldstudyofefficacyandsafetyofpd1antibodymonotherapyandcombinationtherapyinpediatriclymphomapatients AT zizhengxiao realworldstudyofefficacyandsafetyofpd1antibodymonotherapyandcombinationtherapyinpediatriclymphomapatients AT yique realworldstudyofefficacyandsafetyofpd1antibodymonotherapyandcombinationtherapyinpediatriclymphomapatients AT yiwang realworldstudyofefficacyandsafetyofpd1antibodymonotherapyandcombinationtherapyinpediatriclymphomapatients AT yehong realworldstudyofefficacyandsafetyofpd1antibodymonotherapyandcombinationtherapyinpediatriclymphomapatients AT juanwang realworldstudyofefficacyandsafetyofpd1antibodymonotherapyandcombinationtherapyinpediatriclymphomapatients AT suyinglu realworldstudyofefficacyandsafetyofpd1antibodymonotherapyandcombinationtherapyinpediatriclymphomapatients AT juntinghuang realworldstudyofefficacyandsafetyofpd1antibodymonotherapyandcombinationtherapyinpediatriclymphomapatients AT feifeisun realworldstudyofefficacyandsafetyofpd1antibodymonotherapyandcombinationtherapyinpediatriclymphomapatients AT zijunzhen realworldstudyofefficacyandsafetyofpd1antibodymonotherapyandcombinationtherapyinpediatriclymphomapatients AT juanliu realworldstudyofefficacyandsafetyofpd1antibodymonotherapyandcombinationtherapyinpediatriclymphomapatients AT jiaqianxu realworldstudyofefficacyandsafetyofpd1antibodymonotherapyandcombinationtherapyinpediatriclymphomapatients AT yanpengwu realworldstudyofefficacyandsafetyofpd1antibodymonotherapyandcombinationtherapyinpediatriclymphomapatients AT lanyingguo realworldstudyofefficacyandsafetyofpd1antibodymonotherapyandcombinationtherapyinpediatriclymphomapatients AT mjamesyou realworldstudyofefficacyandsafetyofpd1antibodymonotherapyandcombinationtherapyinpediatriclymphomapatients AT jiazhu realworldstudyofefficacyandsafetyofpd1antibodymonotherapyandcombinationtherapyinpediatriclymphomapatients AT yizhuozhang realworldstudyofefficacyandsafetyofpd1antibodymonotherapyandcombinationtherapyinpediatriclymphomapatients |